San Francisco boxing class helps people with Parkinson's fight back against disease
The sport of boxing is having a powerful impact on individuals with Parkinson's disease thanks to a special curriculum in San Francisco called Rock Steady.
For trainer Veronica Garcia Hayes, every day is a push forward. The coach, who has been athletic her whole life, was blindsided by a Parkinson's diagnosis in her 30s.
"I happened to be four months pregnant with my daughter when I received the diagnosis," said Garcia Hayes, who is now 54. "And when you're 39, it is a shock, because you feel like you're just getting your life started."
That shock, however, has become a driving force in her life. Garcia Hayes now leads fitness classes for individuals with Parkinson's, offering support and a sense of community to those facing similar challenges.
"It really is an opportunity for people to be with people in a safe space. Everyone is in the same boat. The camaraderie, I think, is half of the benefit from coming to class," Garcia Hayes told CBS News Bay Area.
Research from Rush University highlights the benefits of boxing for individuals with Parkinson's disease, showing that it helps ease both motor and non-motor symptoms. Beyond the physical improvements, the emotional and social support provided by the classes is equally significant.
"Parkinson's creates a lot of depression, anxiety, apathy," Garcia Hayes explained. "And I think when you surround yourself with people that are in the same situation, it's a safe zone."
For many participants, the class offers more than just physical exercise—it provides a renewed sense of purpose and community. Diane Reyes Surf, a member of Garcia Hayes' class, shared how it has impacted her outlook on life.
"This class makes my day when I come," Reyes Surf said. "The days that I don't have it, it's not fun. Veronica is such an inspiration for everybody in the class."
For Garcia Hayes, the class is an inspiration in return.
"When I come here, and I see the improvement and the happiness on their faces, I leave feeling my spirits are lifted as well. So, it's a win-win I think for both sides," she said.
It's that mutual sense of support and progress that continues to motivate Garcia Hayes to push forward every day.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson's Disease Associated With GBA Mutations
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics ('Capsida') today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class intravenously (IV) administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This is the second wholly owned clinical program developed by Capsida with a cleared IND. Both programs utilize a proprietary IV-delivered, blood brain barrier-crossing engineered capsid and proprietary cargo that is detargeted from off-target tissues, like liver and dorsal root ganglia (DRG). In addition, Capsida uses a proprietary manufacturing process and CAP-003 is manufactured in Capsida's state-of-the-art wholly owned Good Manufacturing Practice (GMP) facility. 'PD-GBA is an area of substantial unmet need given the lack of approved treatments that target GCase, which is the protein encoded by the GBA gene, and provide meaningful slowing or halting of disease progression,' said Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics. 'We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year.' About CAP-003 and the Phase 1/2 Clinical Trial In non-human primate (NHP) studies to date, a single IV infusion of CAP-003 resulted in dose-dependent increases in GCase activity in critical brain regions including the substantia nigra, frontal cortex, caudate nucleus, and putamen substantially above the established 30% efficacy threshold expected to restore enzyme activity levels back to normal in patients with PD-GBA. The NHP Good Laboratory Practices (GLP) toxicology study demonstrated a well-tolerated safety profile with no adverse histopathology. Capsida expects to dose the first patient in the Phase 1/2 clinical trial in the third quarter of this year. For more information about the Phase 1/2 clinical trial, please visit (NCT07011771). About Parkinson's disease associated with GBA mutations (PD-GBA) Mutations in GBA, the gene expressing the GCase enzyme, affect up to 15% of Parkinson's patients and are the most common genetic risk factor for PD. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to healthy individuals 1. There are no approved treatments that target GCase and there are no approved disease modifying treatments for PD. Other investigational treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplement GCase enzyme activity in sufficient quantities to overcome the deficit in patients and impact the disease. In an attempt to overcome these challenges, those treatments have required invasive direct brain or cerebrospinal fluid (CSF) administration, with limited results, and a significant burden for patients. About Capsida Biotherapeutics Capsida Biotherapeutics is a clinical-stage, fully integrated next-generation genetic medicines company. It has a central nervous system (CNS) pipeline consisting of disease-modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes its first-in-class investigational treatment for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), CAP-002; and potential best-in-class investigational treatment for Parkinson's disease associated with GBA mutations (PD-GBA) CAP-003. Both have received FDA Investigational New Drug (IND) clearance to initiate clinical trials. Capsida's pipeline also includes a potential best-in-class treatment for Friedreich's ataxia (FA). In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at 1 Leyns, C. E, G. et al (2023). npj Parkinson's Disease, 74(9).
Yahoo
2 hours ago
- Yahoo
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson's Disease Associated With GBA Mutations
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year THOUSAND OAKS, Calif., June 11, 2025--(BUSINESS WIRE)--Capsida Biotherapeutics ("Capsida") today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class intravenously (IV) administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This is the second wholly owned clinical program developed by Capsida with a cleared IND. Both programs utilize a proprietary IV-delivered, blood brain barrier-crossing engineered capsid and proprietary cargo that is detargeted from off-target tissues, like liver and dorsal root ganglia (DRG). In addition, Capsida uses a proprietary manufacturing process and CAP-003 is manufactured in Capsida's state-of-the-art wholly owned Good Manufacturing Practice (GMP) facility. "PD-GBA is an area of substantial unmet need given the lack of approved treatments that target GCase, which is the protein encoded by the GBA gene, and provide meaningful slowing or halting of disease progression," said Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics. "We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year." About CAP-003 and the Phase 1/2 Clinical Trial In non-human primate (NHP) studies to date, a single IV infusion of CAP-003 resulted in dose-dependent increases in GCase activity in critical brain regions including the substantia nigra, frontal cortex, caudate nucleus, and putamen substantially above the established 30% efficacy threshold expected to restore enzyme activity levels back to normal in patients with PD-GBA. The NHP Good Laboratory Practices (GLP) toxicology study demonstrated a well-tolerated safety profile with no adverse histopathology. Capsida expects to dose the first patient in the Phase 1/2 clinical trial in the third quarter of this year. For more information about the Phase 1/2 clinical trial, please visit (NCT07011771). About Parkinson's disease associated with GBA mutations (PD-GBA) Mutations in GBA, the gene expressing the GCase enzyme, affect up to 15% of Parkinson's patients and are the most common genetic risk factor for PD. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to healthy individuals1. There are no approved treatments that target GCase and there are no approved disease modifying treatments for PD. Other investigational treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplement GCase enzyme activity in sufficient quantities to overcome the deficit in patients and impact the disease. In an attempt to overcome these challenges, those treatments have required invasive direct brain or cerebrospinal fluid (CSF) administration, with limited results, and a significant burden for patients. About Capsida Biotherapeutics Capsida Biotherapeutics is a clinical-stage, fully integrated next-generation genetic medicines company. It has a central nervous system (CNS) pipeline consisting of disease-modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes its first-in-class investigational treatment for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), CAP-002; and potential best-in-class investigational treatment for Parkinson's disease associated with GBA mutations (PD-GBA) CAP-003. Both have received FDA Investigational New Drug (IND) clearance to initiate clinical trials. Capsida's pipeline also includes a potential best-in-class treatment for Friedreich's ataxia (FA). In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at 1Leyns, C. E, G. et al (2023). npj Parkinson's Disease, 74(9). View source version on Contacts Media Contact Inizio Evoke CommsKatherine Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. Key Highlights: ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis. Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment. ENERGI-F705PD aims to combat the root causes of Parkinson's by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis. "We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Parkinson's disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy." About ENERGI-F705PD ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson's disease: Reduce and Prevent α-Synuclein Aggregation: Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of PD. Increase Reducing Power (antioxidant): ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense. Increase Tyrosine Hydroxylase Expression/activity: By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients. About Energenesis Biomedical Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders. The company's robust pipeline includes: ENERGI-F705PD: Oral tablet for Parkinson's disease (Phase I) ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III) ENERGI-F701: Tonic for Alopecia (Phase II completed) ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation(Preparing for Phase II) For more information, please visit Contact: Business Development Team Email: partnership@ View original content: SOURCE ENERGENESIS BIOMEDICAL CO., LTD. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
